Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics' stock has experienced significant volatility and decline. The stock price decreased by 84.02% over the last 12 months, with a year-to-date return of -72.62%. The stock decreased by 54.85% over the past month. As of May 4, 2026, the share price was $0.18, representing a 75.33% decline from May 8, 2025. The company received a Nasdaq notice for non-compliance with the minimum bid price requirement, leading to suspension from The Nasdaq Capital Market and transition to the OTCQB Venture Market. Sangamo plans to request a hearing before a Nasdaq Hearings Panel. Sangamo reported a consolidated net loss of $37.4 million for the fourth quarter ended December 31, 2025, and a consolidated net loss of $122.9 million for the full year 2025. The company raised over $130 million in funding since the start of 2025 through non-dilutive license fees, milestone payments, and equity financing. In April 2025, Sangamo announced a capsid license agreement with Eli Lilly and Company, which included an $18 million upfront license fee and eligibility for up to $1.4 billion in additional fees and milestone payments.

Information regarding the demand seasonality for Sangamo Therapeutics, Inc.'s products and services is not available. Demand for their products, once approved, would likely be driven by medical need rather than typical seasonal consumer patterns.

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company in the Biotechnology industry, focusing on cell and gene therapies for severe genetic diseases and neurological disorders. They translate science into genomic medicines using zinc finger and serine integrase gene editing technologies, along with an AAV-based delivery platform. Their pipeline includes Isaralgagene civaparvovec (ST-920) for Fabry disease, TX200 for kidney transplantation, Giroctocogene fitelparvovec (SB-525) for hemophilia A, and preclinical programs for neurological disorders. The company also has a capsid discovery platform and collaborates with major pharmaceutical companies.

Sangamo Therapeutics is headquartered in Richmond, California, United States. Its stock is listed on the OTCPK, Deutsche Boerse AG (Germany), and the London Stock Exchange (UK), indicating an international presence.

Sangamo Therapeutics is positioned as a genomic medicine company committed to translating science into medicines for patients with severe neurological diseases and other conditions with limited treatment options. Positive developments include topline results from the STAAR study in Fabry disease and the ongoing BLA submission to the FDA for ST-920. Neurology capsid license agreements with companies like Eli Lilly reinforce its position as a collaborator of choice. However, the delisting from Nasdaq could negatively impact the company's brand reputation and investor confidence.

Sangamo Therapeutics, Inc. has 119 institutional owners and shareholders holding a total of 63,010,127 shares. Major institutional owners include Vanguard Group Inc, Renaissance Technologies Llc, Two Sigma Investments, Lp, BlackRock, Inc., Two Sigma Advisers, Lp, Geode Capital Management, Llc, Jane Street Group, Llc, UBS Group AG, Susquehanna International Group, Llp, and Charles Schwab Investment Management Inc. Institutional ownership stands at 16.55% (61.51 million shares), while insider ownership is 2.22% (8.25 million shares).